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Many case-control and cohort studies dating as far back as 1956
have observed the familial aggregation of prostate cancer. Segrega-
tion analyses (e.g. Steinberg et al, 1990) have given support for the
importance of genetic factors in prostate cancer development.
Various models for the mode of inheritance have been proposed. A
cohort study by Monroe et al (1995) suggested that an X-linked or
autosomal recessive susceptibility gene or genes may be involved.
However, a complex segregation analysis performed by Carter et al
(1992) found evidence for a rare highly penetrant prostate cancer
susceptibility gene which is inherited in an autosomal dominant
fashion. Two other studies (Gronberg et al, 1997; Schaid et al, 1998)
found further support for a high-risk dominant model. 
Linkage studies have found some evidence for various loci for
major prostate cancer susceptibility genes. The first chromosomal
localization of a putative prostate cancer gene, HPC1 (hereditary
prostate cancer 1) was suggested by Smith et al (1996) from a
genome wide search in 91 prostate cancer families. This study found
evidence of linkage of the disease to markers on chromosome
1q24–25, with an estimated 34% of these families being linked.
Although three other groups have found some confirmatory evidence
for linkage in a similarly small proportion of such families (Cooney
et al, 1997; Hsieh et al, 1997; Neuhausen et al, 1999), other studies
have failed to find evidence for linkage at this locus (Eeles et al,
1998; Cannon-Albright and Neuhausen, 1997; McIndoe et al, 1997;
Thibodeau et al, 1997). A recent meta-analysis combining these
published and new data from these groups has estimated that only
6% of families worldwide are linked to this locus (Xu et al, 2000). In
a recent genome screen of multiplex sibships with prostate cancer,
Suarez et al (2000) found nominally significant linkage at two distal
markers approximately 20cM from the putative HPC1 region.
More recently another prostate cancer susceptibility locus has
been described by Xu et al (1998) on the X chromosome at
Xq27–28. This locus was estimated to account for approximately
16% of the prostate cancer families studied. A subsequent study by
Lange et al (1999) has provided further support for the existence of
a prostate cancer susceptibility gene in this region in a linkage
study of 153 families with at least two members affected with
prostate cancer. 
These findings suggest that locus heterogeneity is a feature of
this disease and there may be several major susceptibility loci
involved. 
Berthon et al (1998) reported evidence for linkage to the region
1q42.2–43 from a study of 47 French and German multiple-case
families with a maximum two-point LOD score of 2.7 at marker
D1S2785. Their heterogeneity analysis estimated that the proportion
of families with linkage to this locus could be as high as 50%. In a
stratified analysis of nine families with early-onset prostate cancer
(age less than 60 years at diagnosis), multipoint LOD and NPL
scores of 3.31 and 3.32 (P = 0.001) respectively, were obtained with
an alpha of approximately 20%. They named the putative suscepti-
bility gene in this region PCaP (predisposing gene for cancer of the
prostate). Gibbs et al (1999) also performed a linkage analysis of
this region in 152 prostate cancer families. Both parametric and non-
parametric analysis revealed no significant evidence of linkage.
Further analysis of family subsets, stratified according to mean age
of diagnosis and number of affected members, did not provide any
significant evidence for linkage. In a further attempt to confirm the
findings by Berthon et al, Whittemore et al (1999) conducted a
linkage study in 97 families with at least three affected cases using
three markers. Multipoint LOD and NPL scores failed to support
linkage, even when analysis was restricted to the 14 families in their
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set with early-onset disease. In the genome search by Suarez et al
(2000), nominally significant evidence for linkage was found at two
markers in the PCaP region in a subgroup of families with late-age-
at-onset prostate cancer. 
The aim of our study was to attempt to confirm the findings 
of Berthon et al (1998) by performing linkage analysis in 131
prostate cancer families from the ACTANE Consortium using
microsatellite markers in the 1q42.2–43 region. 
MATERIALS AND METHODS 
Family selection 
A total of 131 families were selected from the ACTANE Consortium
(excluding Canada) for this study. The criteria for selection were:
three or more relatives affected with prostate cancer in a family, or a
relative pair affected with the disease, one or both of whom were
aged 65 years or less at diagnosis. The ACTANE consortium is a
collaboration between the Cancer Research Campaign (CRC)/British
Prostate Group (BPG) UK Familial Prostate Cancer Study (Anglo)
and other groups worldwide with prostate cancer family sets from
Canada, Texas, Australia, Norway, EU Biomed. Families were
collected as follows: 
UK group 
All families were recruited through collaborating urologists,
geneticists and oncologists via the CRC/BPG UK Familial Prostate
Cancer Study. Within these families 97% of cases were clinically
detected and the remaining 3% were diagnosed as a result of a
prostate-specific antigen (PSA) screen. Details of family history
were obtained from questionnaires completed by the index case.
Cases of prostate cancer were confirmed by pathology reports,
self-report, medical records or death certificates. 
Texan group 
Index cases were patients referred to the UTMD Anderson Cancer
Centre, Houston, Texas, whose diagnoses of prostate cancer were
subsequently confirmed by pathology review. 
Australian group 
Families were recruited from the ‘Risk factors for Prostate
Cancer’ study which is a population-based case-control study
conducted in Melbourne, Sydney and Perth. All probands had
histopathological confirmation of prostate cancer. Reported
prostate cancer cases in family members were confirmed wher-
ever possible by matching against the National Cancer Registry
and National Death Index. 
Norwegian group 
Families were recruited from the cancer genetics clinic at the
Norwegian Radium Hospital and were included if prostate cancer
affected: at least three relatives in the same lineage regardless of
age of onset; or a relative pair with one aged 65 years or younger at
diagnosis. Diagnosis in the prostate cancer cases was verified from
the medical records. For family members reported by the cases to
have prostate cancer, the diagnosis was verified by the National
Cancer Registry or by the medical records when possible. 
EU Biomed group 
These families were collected from major urological centres
across Europe. These centres have been participating in the
collection of families for the analysis of high- and low-penetrance
genes in prostate cancer. Only those cases in whom the diagnosis
of prostate cancer could be verified from histological or medical
records were included in the analysis. Breakdown of families by
centre, number of affected members and age at diagnosis is shown
in Table 1. 
Full approval for this study was obtained from the Research
Ethics Committee. 
Genotype analysis 
DNA for analysis was extracted from lymphocytes from blood
samples provided by both affected and unaffected family members
in the study. All individuals were genotyped using four polymor-
phic markers spanning the PCaP candidate region of 1q42.2–43 as
reported by Berthon et al (1998). The dinucleotides used were
D1S2850-11.2cM-D1S2785-1.2cM-D1S321-6.0cM-D1S2842.
Sex-averaged distances between markers were taken from genetic
maps from the Marshfield Medical Research Foundation (Broman
et al 1998). Samples from all collaborating groups were genotyped
at one centre. 
PCR was performed as follows: one primer of each pair was
radiolabelled with 32P using 32P (γ -dATP) and T4 polynucleotide
kinase (PNK) in the presence of PNK-ligase buffer; the reaction
mixture contained 1.5 µ l of KCL Tris PE Buffer (× 10), 0.60 µ l 1.0
mM MgCl2 (Perkin Elmer) for markers D1S321 and D1S2785 /
2.0 mM MgCl2 for marker D1S2850/ 1.5 mM MgCl2 for marker
D1S2842, 0.15 µ l (final concentration 1.0 mM) total deoxynu-
cleotide triphosphates (Stratagene), 0.15 µ l of each primer (Oswel)
at final concentration of 0.30 µ M, 0.6 units Perkin Elmer gold Taq
Polymerase, 5 µ l genomic DNA (5 ng µ l–1) and water to a total
volume of 15 µ l. PCR was performed on a Hybaid thermocycler
using annealing temperatures optimized for each primer, for a total
of 35–40 cycles. PCR products were loaded onto 6% denaturing
polyacrylamide gels. Controls of known size were loaded at
regular intervals to act as size markers. Gels were run at 80 W for
2.5–3.0 h, dried and then exposed to X-ray film for 12 h to 3 days.
Alleles were then scored visually by one observer and confirmed
by a second observer. Allele scores were assigned on the basis of
comparison with the CEPH family member 1347-02 who was used
as a control individual. Control allele frequencies for each marker
were derived from the CEPH family database (Dausset et al, 1990) 
Statistical analysis 
Linkage of prostate cancer to the region 1q42.2–43 was first asses-
sed by parametric LOD score analysis, based on the prostate-cancer-
Table 1 Family breakdown by centre, age and number of affected members 
Number of  UK Texas Australia Norway EU Biomed Total 
cases
Two affected 32 3 14 1 1 51 
Three or four 
affected 32 5 24 2 4 67 
Five or more 
affected 5 5 1 2 0 13 
Total 69 13 39 5 5 131 
a Age < 65 30 3 22 3 2 60 
a Age ≥ 65 39 10 17 2 3 71 
aAge figures refer to average age at diagnosis of affecteds. susceptibility model suggested by Carter et al (1992). This model
assumes that prostate cancer susceptibility is due to a dominant gene
with a population frequency of 0.003 and an overall penetrance of
88% by 85 years of age in carriers. This was also the basis of the
models used by Berthon et al (1998) in their linkage analysis. Two-
point LOD scores were calculated using Fastlink (Cottingham et al,
1993; Schäffer et al, 1994). Multipoint heterogeneity LOD (HLOD)
scores were computed using Genehunter (Kruglyak et al, 1996) over
the 18 cM distance spanned by the four markers. Families too large
for exact computation by Genehunter were analysed using Vitesse
(O’Connell et al, 1995). 
Due to doubt regarding the appropriate model for age-specific
prostate cancer susceptibility, non-parametric linkage scores were
calculated to compare identical-by-descent sharing among all
affecteds in a pedigree, with that expected under no linkage. 
Analysis was performed across the whole family set and then in
subsets stratified according to: number of affected men per family;
and average age at diagnosis (age < 65 years and age ≥ 65 years). 
RESULTS 
LOD scores from the two-point parametric analysis are given in
Table 2. The results show no evidence for linkage at any marker.
The largest positive LOD score was 0.40 at DIS2850 with recom-
bination fraction θ = 0.2. 
Non-parametric multipoint analysis using Genehunter found no
evidence of linkage to 1q42.2–43 at marker D1S2785 either for all
families combined (multipoint NPL score = –0.12, P = 0.55) or
separately, according to number of cases affected per family: two
cases (multipoint NPL score = –0.44, P = 0.67); three or four cases
(multipoint NPL score = 0.08, P = 0.46); ≥ five cases (multipoint
NPL score = 0.30, P = 0.35). Analysis was also performed in
family subsets according to average age at diagnosis: under 65
years (multipoint NPL score = 0.12, P = 0.45) and 65 years and
over (multipoint NPL score = –0.27, P = 0.60). 
The results of the multipoint heterogeneity analyses are shown
in Tables 3 and 4. The results do not provide any evidence of
linkage at 1q42.2–43, the overall HLOD score for all 131 families
was 0.00 and the estimated proportion linked (α ) was 0 (95% CI =
0.00–0.33). For families with five or more cases, the HLOD was
0.01, with α = 0.16 (95% CI = 0–1); for families with only two
cases the HLOD was also 0.00, with α = 0 (95% CI = 0.00–0.57).
Analysis stratified by age at diagnosis showed that for the 60 fami-
lies that had at least two members diagnosed at age 65 years or
less, HLOD was 0.00 (α = 0) while the HLOD for the other 71
families was 0.01 (α = 0.07). 
The results presented in Table 4 have assumed that the candidate
gene lies midway between markers D1S2785 and D1S321, as was
suggested by the peak LOD scores obtained in this region by
Berthon’s group. Therefore, we also performed heterogeneity and
sub-group analyses, maximizing the position of the putative
susceptibility gene over the whole 18 cM region. Results showed
little change: the maximum HLOD score was only 0.37 (α = 0.32),
obtained at the location of marker D1S2850, in families containing
three or four cases. 
DISCUSSION 
Analyses of the set of 131 ACTANE prostate cancer families
overall showed no significant evidence of linkage to 1q42.2–43
region using four markers flanking the putative PCaP region 
(two-point LOD = –0.89 to –11.39, across the region of maximum
multipoint LOD reported by Berthon et al, 1998). Overall the es-
timated proportion of families linked was zero, although we could
not confidently exclude values less than one-third. Stratification
of the family set into sub-groups according to average age at
1656 The ACTANE Consortium
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Table 3 Multipoint linkage analysis of 131 families (non-parametric analysis) 
Marker and  Multipoint  α MultiPoint Multipoint P




0.00 –5.31 0.12 0.05 0.09 0.46 
2.25 –4.72 0.11 0.03 0.05 0.48 
4.50 –5.01 0.09 0.02 0.01 0.49 
6.75 –5.98 0.07 0.01 –0.03 0.51 
9.00 –7.86 0.05 –0.00 –0.08 0.53 
D1S2785 
11.25 –12.41 0.04 –0.00 –0.12 0.54 
11.50 –12.12 0.04 –0.00 –0.12 0.54 
11.75 –11.91 0.03 –0.01 –0.12 0.55 
11.99 –11.74 0.03 –0.01 –0.13 0.55 
12.24 –11.62 0.03 –0.01 –0.13 0.55 
D1S321 
12.49 –11.54 0.03 –0.01 –0.13 0.55 
13.68 –10.78 0.02 –0.01 –0.17 0.56 
14.87 –10.34 0.02 –0.01 –0.21 0.58 
16.06 –10.15 0.02 –0.01 –0.24 0.59 
17.25 –10.16 0.01 –0.01 –0.27 0.60 
D1S2842 
18.44 –10.38 0.01 –0.01 –0.31 0.62
Table 3 Multipoint linkage analysis of 131 families (non-parametric analysis) 
Families Multipoint HLOD  scorea α (95% CI)  P
Lod score NPL score
All  11.91 0.00 0.00 (0.00–0.33)  0.12
0.55
Two cases  2.33 0.00 0.00 (0.00–0.57)  0.44
0.67
Three/four
cases  8.95 0.01 0.07 (0.00–0.43) 0.08
0.46
five-plus
cases  0.62 0.01 0.16 (0.00–1.00) 0.30
0.35
Age   65  7.07 0.00 0.00 (0.00–0.43) 0.12
0.45
Age > 65 24.84 0.01 0.07 (0.00–0.49) 20.27
0.60
aAssuming heterogeneity
Table 2 Two-point LOD scores for four markers on chromosome 1q42.2–43 
Recombination fraction (θ ) 
Marker 0.0 0.01 0.05 0.1 0.2 0.3 0.4 
D1S2850 –2.53 –2.04 –0.82 –0.07 0.40 0.31 0.10 
D1S2785 –11.39 –9.64 –5.94 –3.57 –1.31 –0.42 –0.08 
D1S321 –0.89 –0.65 –0.07 0.26 0.38 0.24 0.07 
D1S2842 –8.45 –7.38 –4.72 –2.85 –1.00 –0.28 –0.05 No evidence of linkage to chromosome 1q42.2–43 1657
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diagnosis and number of affected family members also yielded no
evidence of linkage. 
Our findings are similar to those of Gibbs et al (1999) and
Whittemore et al (1999) who also failed to find evidence of
linkage after analysis according to a similar stratification. Such
conflicting evidence regarding linkage to this region on chromo-
some 1 may be influenced by various factors, particularly with
respect to the sample set. Indeed, some differences exist in the
profiles of families used in this study. Berthon’s group used 47
families of French and German origin only while our study
comprised 131 families of both European and North American
origin. All French and German families studied had a minimum of
three members affected with the disease, while we included fami-
lies with only two members affected. However, it seems unlikely
that these differences alone could account for the discrepancy in
results found between the two groups. Whittemore et al (1999)
used only three markers to genotype 82 families of predominantly
American origin. Similarly, out of the 152 families used in the
study by Gibbs et al (1999) only six were of non-white origin, the
rest were white American. Thus our study used a wider cross-
section of families of diverse international origin.
Berthon et al (1998) also looked for loss of heterozygosity
(LOH) at 1q42.2–43 in addition to linkage. Allelic loss in this
region was seen in 11 tumours, of which five also had overlapping
alterations in the 1q24–25 area. This finding of LOH is of par-
ticular interest because there is another putative locus, HPC1 
at 1q24–25 (Smith et al, 1996). We have yet to carry out LOH
studies, but this will be undertaken as part of a future study. 
In conclusion, this analysis of 131 multiple-case prostate cancer
families failed to show evidence of linkage at chromosome
1q42.2–43. It is becoming increasingly evident from the results of
recent linkage studies in this field that several major loci may be
involved in the increased susceptibility to inherited prostate
cancer. Thus, in the presence of such genetic heterogeneity, it may
be difficult for different groups to replicate linkage to an infre-
quent locus which may account for only a small proportion of
families. Evaluation of further extended pedigrees and meta-
analyses of large data sets are therefore crucial in the successful
identification of prostate-cancer-susceptibility loci. 
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